Oct 16 (Reuters) - Novartis (NOVN.S), opens new tab has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from ...

Novartis NOVN-1.67%decrease; red down pointing triangle raised its guidance for the third time this year after higher third-quarter results topped expectations, boosted by revenue from its ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali. The Swiss pharmaceutical ...

Novartis has terminated a phase 2 trial of its SMURF1 inhibitor LTP001 in idiopathic pulmonary fibrosis (IPF) but will continue to advance the candidate in another indication. The Swiss drugmaker ...

Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an accelerated approval to treat newly diagnosed patients. Tuesday ...

Novartis has a long way to go to make its twice-yearly cholesterol-lowering drug Leqvio the multi-billion-dollar blockbuster it is predicting – but took another step along that road today.

LONDON — Novartis on Tuesday increased its earnings guidance for the third time this year, boosted by strong sales of its leading drugs. The company said it anticipates full-year operating ...

LONDON — It hasn’t even been a year since Pfizer closed its $43 billion acquisition of Seagen — one of the biggest biopharma deals in years — but David Epstein, who was CEO of Seagen, is back.

As expected, Novartis’ radioligand therapy Pluvicto crossed the blockbuster sales threshold with one quarter still left of 2024. But some may not be satisfied with the prostate cancer med’s ...

Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. The deal, which features $1.1 billion in milestones, covers the global rights to a small ...

Truist highlights Novartis' strong balance sheet, which enables further bolt-on deals and share buybacks. Recent transactions primarily involve deals in the sub-$1 billion range, along with a few ...